Objective: mRen2.Lewis rats exhibit exacerbated increases in blood pressure, left ventricular (LV) remodeling, and diastolic impairment after the loss of estrogens. In this same model, depletion of estrogens has marked effects on the cardiac biopterin profile concomitant with suppressed nitric oxide release. With respect to the establishment of overt systolic hypertension after oophorectomy (OVX), we assessed the effects of timing long-term 17A-estradiol (E 2 ) therapy on myocardial function, myocardial structure, and the cardiac nitric oxide system.
H eart failure is a major health problem with significant morbidity and mortality. It is more frequently associated with left ventricular (LV) diastolic dysfunction in women than in men owing to increased cardiac stiffness, for which there is no specific treatment. 1<4 Diastolic heart failure accounts for 40% to 60% of chronic heart failure cases, 5 and more than 75% of these cases occur in older women. 6<8 Evidence suggests that the loss of estrogens in postmenopausal women contributes to the development of hypertension and cardiac hypertrophy, 2 which are risk factors for diastolic dysfunction. Women seem to be protected from LV diastolic dysfunction before menopause, with a rapid increase in incidence after menopause. 2, 9 These observations underscore the importance of female sex hormones, particularly estrogen, in regulating blood pressure, diastolic function, and LV remodeling. However, the mechanisms by which estrogens exert cardiovascular protection remain poorly understood, and the appropriate timing for initiation of estrogen therapy continues to be controversial. 10<12 The results of the Women's Health Initiative and the Heart and Estrogen/progestin Replacement Study stimulated new interest in the timing of initial estrogen therapy in relation to cardiovascular differences between perimenopausal and postmenopausal women. 13, 14 The Heart and Estrogen/progestin Replacement Study found that estrogen-progestin therapy in postmenopausal women reduced the risk of coronary heart disease on years 3 to 5 after initiation of therapy but caused an unexpected 50% increase in risk during the first year of therapy, resulting in an overall null effect. Thus, timing may be the key to maximizing potential benefits and minimizing the adverse effects of hormone therapy. 15<17 It was hypothesized that the vessels and myocardium of older postmenopausal women undergo significant age-related remodeling and pathology, including systolic hypertension, such that Blate[ initiation of estrogen therapy (Q10 y after the loss of ovarian hormone production) may not reverse cardiovascular damage or prevent further disease progression. 12 Although ongoing clinical trials (including the Early versus Late Intervention Trial with Estradiol [http://clinicaltrials.gov/ct2/show/NCT00114517] and the Kronos Early Estrogen Prevention Study 18 ) are starting to provide insight into the validity of the timing hypothesis, animal models that replicate many of the critical cardiovascular features of aging women (hypertension, concentric LV hypertrophy, and diastolic dysfunction) can help determine whether the timing of estrogen therapy affects the prevention, slowing, or reversal of the structural and functional cardiac defects that develop in postmenopausal women.
The female mRen2.Lewis rat is particularly well suited for testing the timing hypothesis. The mRen2.Lewis rat is a congenic rodent model of angiotensin IIYdependent hypertension. The female mRen2.Lewis rat, ovariectomized at the age of 4 to 5 weeks, is a well-established animal model of sex-specific diastolic dysfunction that corresponds to the cardiovascular phenotype of postmenopausal women. Early bilateral oophorectomy (OVX) of this model consistently exacerbates increases in systolic blood pressure, LV remodeling (including collagen deposition and myocyte hypertrophy), and impairment of diastolic function. 19<22 The present study mimicked early and late estrogen (17A-estradiol [E 2 ]) therapies and their resulting clinical effects by determining the myocardial effectiveness of long-term E 2 therapy before and after the establishment of overt hypertension in OVX mRen2.Lewis rats. The structural and functional LV phenotypes were compared across four groups of age-matched littermates: (1) untreated OVX rats; (2) rats that received Bearly[ E 2 , initiated at the time of surgical OVX; (3) rats that received Blate[ E 2 , initiated 6 weeks after OVX, when systolic hypertension was already well established in this model; and (4) estrogen-intact rats that underwent sham operation (Sham). Previous research using this model showed that estrogen deprivation resulted in a reduction in tetrahydrobiopterin (BH 4 ), a cardiac biopterin required for neuronal nitric oxide synthase to produce nitric oxide rather than reactive oxygen species. 20, 21 Therefore, we also determined the effects of Bearly[ and Blate[ E 2 therapy on nitric oxide production and cardiac biopterins (dihydrobiopterin [BH 2 ], BH 4 , and total biopterins).
METHODS

Animals
Female mRen2.Lewis rats were obtained from the Hypertension and Vascular Research Center Congenic Colony at Wake Forest School of Medicine. All studies were approved by the institution's Animal Care and Use Committee. All animal procedures conformed to the Guide to the Care and Use of Laboratory Animals published by the US National Institutes of Health. Rats were weaned at 3 weeks of age, allowed to acclimate to a temperature-controlled (22-C [2-C]) and light-controlled (12-h light/dark cycle) facility approved by the Association for Assessment and Accreditation of Laboratory Animal Care, and provided food and water ad libitum.
Experimental protocol
Rats were separated randomly into four groupsVSham (n = 13), OVX (n = 9), OVX + E 2 -early (n = 7), and OVX + E 2 -late (n = 8)Vand housed individually throughout the experiment. At 4 weeks of age, rats underwent either bilateral OVX or a sham procedure under anesthesia by inhalation of isoflurane, as described previously. 20<22 Estrogen depletion, via OVX, in young mRen2.Lewis rats has consistently been found to have a marked stimulatory effect on the progression of increased systolic blood pressure, cardiac hypertrophy, and impaired LV relaxation. 19<23 These characteristics were not as apparent when OVX was performed at 10 weeks of age (unpublished data). In fact, the kidneys of late OVX mRen2.Lewis rats, compared with ovary-intact littermates, were protected from high salt intake, independent of blood pressure. 24, 25 Thus, the early OVX mRen2.Lewis female rat reliably exhibits features that emulate the cardiovascular phenotype of older postmenopausal women, making it an ideal model for studying the role of estrogen therapy in the maintenance of diastolic function. Immediately at the time of OVX, the E 2 -early rats were implanted subcutaneously in the posterior neck with 60-day-release E 2 pellets (36 Kg per pellet; Innovative Research of America, Sarasota, FL). At 13 weeks of age, the pellets were replaced to maintain continual hormonal coverage for the 10-week treatment period. The E 2 -late rats received subcutaneous E 2 treatment via pellets from weeks 11 to 15. The achievement of physiological levels of circulating estrogens by subcutaneous estradiol therapy and the successful depletion of circulating estrogens by OVX were confirmed using a serum estradiol assay (5 pg/mL detection limit; Plymedco, Cortlandt Manor, NY) at the end of the experiment.
Weekly body weight and systolic blood pressure by the tail cuff (NIBP-LE5001; Panlab, Barcelona, Spain) were monitored throughout the study. At 15 weeks of age, rats were euthanized via exsanguination by cardiac puncture while under ketamine/xylazine anesthesia (ketamine HCl 60 mg/kg and xylazine HCl 5 mg/kg) after echocardiographic evaluation. Whole hearts were isolated and further dissected to isolate the left ventricle, right ventricle, and atria. Tissue weights were measured with an analytical scale. The left ventricle was cut into pieces for biochemical and histological analyses.
Medical Systems, Andover, MA) and a 5-to 12-MHz pediatric phased-array probe (s12 Philips; Philips Medical Systems). All measurements were made in accordance with the conventions of the American Society of Echocardiography and were conducted by the same investigator who was blinded to the experimental groups. For the procedure, animals were anesthesized with an intramuscular injection of ketamine HCl 60 mg/kg and xylazine HCl 5 mg/kg. LV end-diastolic dimension (LVEDD), LV end-systolic dimension (LVESD), LV posterior wall thickness (PWT), and LV anterior wall thickness (AWT) at the end of diastole were measured from midpapillary short-axis images obtained by M-mode echocardiography. The percentage of LV fractional shortening (FS), an index of contractile function, was calculated as FS (%) = [(LVEDD j LVESD) / LVEDD] Â 100. LV mass was calculated using a standard cube formula, which assumes a spherical LV geometry according to the formula: LV mass = 1.04 Â [(LVEDD + PWT + AWT) 3 j LVEDD], where 1.04 is the specific gravity of muscle. Relative wall thickness (RWT) was calculated as: 2 Â PWT / LVEDD. LV diastolic function was assessed using conventional and tissue Doppler imaging. From an apical four-chamber orientation, early transmitral filling velocity (E max ), late transmitral filling velocity (A max ), and early deceleration time (E dec ) were obtained with the Doppler sample volume placed at the mitral valve leaflet tips. The ratio of early transmitral filling to late transmitral filling (E/A) was calculated. Early mitral annular descent (e ¶) and the ratio of early filling velocity to early mitral annular velocity (E/e ¶) were obtained using pulsed tissue Doppler imaging. All measurements were performed by a masked investigator using an offline analysis system (Xcelera 3.1; Koninklijke Philips Electronics, the Netherlands). At least five consecutive cardiac cycles, on average, were used to minimize beat-to-beat variability for all measured and calculated systolic and diastolic indices.
Histopathologic evaluation
A horizontal short-axis section of the formalin-fixed heart was taken through the left ventricle, from its equator between the apex and the base. Specimens were dehydrated through an ethanol series and embedded in paraffin. After microtome sectioning, the 4-Km tissue specimens underwent Verhoeff van Gieson staining for assessment of collagen and elastin fibers. An observer who had no knowledge of treatment groups and previous results examined the sections with light microscopy (25Â objective), using a Zeiss AxioCam digital camera and AxioVision software (Zeiss, München-Hallbergmoos, Germany). Multiple digital images were obtained, and the percentage of perivascular collagen was calculated as: total perivascular collagen area j vessel luminal area / total perivascular collagen area Â 100, using the ImageJ program (National Institutes of Health). 26, 27 For each left ventricle, five nonepicardial coronary arteries, on average, were found to be suitable (eg, cross-sectional cut) for morphometric analysis. One average value for the perivascular collagen area ratio was used for each specimen.
Cardiac biopterins
Cardiac tissue BH 4 levels were measured by high-performance liquid chromatography with fluorescence detection, as previously documented. 20, 21 Total biopterins (BH 4 , BH 2 , and oxidized biopterin) were measured after acid oxidation of the deproteinated cardiac supernatant. BH 2 plus oxidized biopterin was determined by alkali oxidation, followed by iodine reduction and acidification. The resulting samples were centrifuged, and small aliquots were injected into a Spherisorb ODS-1 column (5 Km particle size, 250 mm long, 4.6 mm inner diameter; Alltech Associates Inc, Deerfield, IL). Fluorescence (350 nm excitation, 450 nm emission) was detected by a fluorescence detector (RF10AXL; Shimadzu Co, Columbia, MD). BH 4 concentration was calculated by subtracting BH 2 and oxidized biopterin from total biopterins.
Cardiac nitrite
Nitrite levels were determined using a chemiluminescencebased nitric oxide analyzer (Sievers Inc, GE Analytical Instruments, Boulder, CO), as previously described. 20, 21 Standard curves were obtained and used for quantitative measurements.
Statistical analysis
All values are expressed as mean (SEM). All statistical analyses were performed using GraphPad Prism version 5 (GraphPad, San Diego, CA). All endpoints were statistically evaluated by one-way analysis of variance with Tukey's multiple comparisons test for post hoc determination of significant differences. Differences were considered significant at P G 0.05.
We performed a linear trajectory analysis to estimate the predicted systolic blood pressure over time for each group. We used this model to examine the difference in slopes between groups before and after the 11-week intervention. 
RESULTS
The OVX mRen2.Lewis rat is a well-established animal model of female sexYspecific diastolic dysfunction that emulates the cardiovascular phenotype of the postmenopausal woman, 19<23 specifically systolic hypertension, LV hypertrophy, impaired relaxation, and elevated filling pressure. As expected, animals in the OVX group had significantly greater body weights than those in the two E 2 -treated groups or the sham-operated group: OVX 269 (20) g versus Sham 239 (7) g; E 2 -early, 198 (22) g; E 2 -late, 241 (14) g; P G 0.05. Body weights in the OVX group receiving E 2 supplementation beginning at the time of surgical operation (E 2 -early) were lower than the Sham and E 2 -late therapy groups (P G 0.05). The efficacy of surgical bilateral OVX was also confirmed by the significant reduction in serum E 2 levels in OVX rats compared with their cycling sham-operated littermates: 27 pg/mL versus undetectable level (G5 pg/mL), respectively. Four weeks (E 2 -late) and 10 weeks (E 2 -early) of subcutaneous E 2 supplementation to OVX rats increased plasma estradiol levels up to 37 and 131 pg/mL, respectively, which were within the physiological range of cycling rodents. 23, 28, 29 Consistent with our previous studies, 20,21 substantial increases in systolic blood pressure were observed by 8 weeks of age in OVX rats when compared with intact littermates, with a subsequent plateau by 11 weeks of age or at a systolic blood pressure of about 165 mm Hg (Fig. 1) . In the Bearly[ E 2 therapy group, systolic blood pressure peaked by 8 weeks of age or at 125 mm Hg, and this pressure was maintained until the completion of the protocol. Interestingly, the blood pressure profile of the Bearly[ group was lower than that observed among sham-operated, estrogen-intact rats. The blood pressure rise and plateau profile of the Blate[ estrogen treatment group were not different from those of OVX vehicle-treated rats.
The early surgical loss of ovarian estrogens (at 5 wk of age) led to significant increases in heart weight by 15 weeks of age (Table 1 ). The whole heart weight increased by 13% in OVX rats compared with sham-operated rats (P G 0.05). Because the body weight in OVX rats was also increased, the heart weight/body weight ratios were not different among groups. Even so, the wall thicknesses and LV mass, as determined by M-mode echocardiography, were significantly increased in OVX rats compared with their sham-operated littermates. Although E 2 -early therapy limited the effects of ovarian estrogen loss on AWT and LV mass (P G 0.05), its effects on heart weight and RWT were only modest. Moreover, E 2 -late treatment attenuated OVX-related increases in LV mass and tended to attenuate increases in AWT, PWT, and RWT (P 9 0.05; Table 1 ).
The diastolic functional potential of early and late estrogen administration in OVX mRen2.Lewis rats was evaluated in this study using both conventional and tissue Doppler echocardiography. Although the conventional Doppler indices of diastolic function were not different among treatment groups (Table 2) , the tissue DopplerYderived index of LV filling pressure (E/e ¶) was adversely affected by the loss of ovarian estrogens when compared with sham-operated and E 2 -treated rats (Fig. 2 ). Myocardial relaxation (e ¶) was reduced in OVX rats versus intact and estrogen-treated rats, but statistical significance was only apparent between OVX and E 2 -late therapy. Interestingly, there were no differences in e ¶ or E/e ¶ between E 2 -earlyYtreated and E 2 -lateYtreated OVX rats, nor were there differences between E 2 -treated rats and age-matched cycling littermates. Systolic function, as determined by FS, was not affected by the loss of estrogens or the administration of estradiol (Table 1) .
Consistent with our previous findings, perivascular collagen deposition was significantly enhanced in LV sections from OVX mRen2.Lewis rats when compared with shamoperated littermates: OVX 0.49% (0.10%) versus Sham 0.36% (0.09%), P G 0.05. This increase in perivascular fibrosis was attenuated by both early and late estradiol supplementation (P G 0.0001). There were no differences in collagen deposition between E 2 -earlyYtreated and E 2 -lateY treated rats ( Fig. 3 ).
Our previous data show enhanced reactive oxygen species generation and reduced nitric oxide production in the hearts of OVX mRen2.Lewis rats, 20 presumably owing to a relative deficiency in BH 4 . Consistent with our previous findings, 20,21 cardiac BH 2 levels were increased whereas BH 4 concentrations were decreased in the hearts of OVX rats compared with sham-operated rats (Fig. 4) . The OVX-related changes in BH 2 were significantly inhibited by 4 weeks (late) and 10 weeks (early) of E 2 supplementation. Notably, the levels of this biopterin component were similar to those in cycling sham-operated littermates. Cardiac BH 4 levels were modestly increased by E 2 -early and E 2 -late therapies compared with hearts from OVX rats, although levels did not achieve significance. Nitrite has been shown to be a good indicator of nitric oxide synthase activity. 30 As we reported previously, 20 the cardiac indicator of nitric oxide productionVnitriteVwas significantly reduced in OVX mRen2.Lewis rats when compared with sham-operated rats. The OVX-related reduction in cardiac nitric oxide production was significantly inhibited by E 2 -late therapy, and there was a tendency for cardiac nitric oxide to also increase in the E 2 -early group (P = 0.13). Moreover, cardiac nitrite levels in OVX-treated rats were similar to those in cycling animals (Fig. 4) .
DISCUSSION
Although the results of preclinical studies in animal models documented a cardioprotective effect of estrogen therapy, 23,31<33 large clinical trials did not show protective cardiovascular benefits in women who received conjugated equine estrogens after the onset of menopause. 11, 13, 14, 34 Estrogen administration in human studies usually occurred many years after menopause. In contrast, previous studies using animal models often administered estrogen immediately after OVX. The present study compared the cardiac effects of E 2 -early and E 2 -late administration, and resulted in several important findings. First, estrogen therapy immediately after OVX or initiated 6 weeks after OVX had an equally similar impact on decreasing LV filling pressures (E/e ¶) and improving cardiac remodeling. Second, these cardioprotective effects of E 2 were independent of systolic blood pressure because the pressures in E 2 -early rats were actually lower than those measured in sham-operated, estrogen-intact rats, whereas the pressures in E 2 -late rats were comparable to those assessed in untreated OVX littermates. Third, the effects of E 2 , particularly when initiated after the blood pressure had reached a hypertensive plateau, seem to be dependent on decreases in cardiac BH 2 in the presence of augmentations in BH 4 and nitrite.
In the present study, estrogen therapy was started either early (immediately after OVX) or late (6 wk after OVX), a time when exacerbated increases in blood pressure reach a hypertensive plateau in this model. 20, 21 In the E 2 -early group, blood pressure decreased significantly compared with the control group, starting 4 weeks after pellet implantation. The change in blood pressure after OVX and the effect of E 2 -early treatment are consistent with the results of previous studies on ovariectomized mRen2.Lewis rats, 23 spontaneously hypertensive rats (SHRs), 35 stroke-prone SHRs, 36 deoxycorticosterone acetate saltYinduced hypertensive rats, 37 and Dahl saltYsensitive rats. 38 However, after blood pressure had reached a higher hypertensive plateau, E 2 -late therapy did not reduce the pressure, even though serum estradiol levels should have been similar 4 weeks after pellet implantation in the early and late groups, and not significantly different from those in intact rats. The irreversibility of increased blood pressure in E 2 -late rats may have been a consequence of the adverse structural remodeling of resistant vessels brought about by the changed neurohormonal mechanisms associated with the evolution of hypertension. 39, 40 Another explanation for the absence of an overt estrogenic response to blood pressure in the E 2 -late group might be estradiol dosing and/or its potency to the novel receptor estrogen receptor GPR30 on vascular smooth muscle. Although Lindsey et al 41 showed that GPR30 contributes to the estrogen-dependent regulation of blood pressure in mRen2.Lewis rats, the 400 Kg/kg/day dosing of the GPR30-specific agonist (G1) used in their studies was based on a dose of estradiol (1.0 mg/pellet) 23 higher than that in the current study (0.36 Kg/pellet). Indeed, the activation of GPR30 by different doses of G1 or E 2 could have different effects on blood pressure. We recently reported that long-term G1 administration (50 Kg/kg/d) to mRen2.Lewis rats did not alter exacerbated elevations in blood pressure 6 weeks after OVX. 22 Despite the significant differences between E 2 -early and E 2 -late treatments in final blood pressure and blood estradiol concentration, the two groups did not differ in diastolic function or measured indices of cardiac remodeling. These data suggest that ventricular relaxation processes are uncoupled from the load that increased vascular resistance imposes on cardiac dynamics. Although our original idea was that E 2 -early treatment might offer additional benefit over E 2 -late treatment in attenuating the adverse effects of OVX on diastolic function and cardiac structure, the current findings did not support this hypothesis. Even though the reasons for this are not clear, our results indicate that the protective effects of E 2 may have been caused by the inhibition of OVX-induced increases in renin-angiotensin system activity. 23 Previous studies also showed that estradiol directly attenuated angiotensin II, phenylephrine, or endothelin-1Yinduced hypertrophy in cardiomyocytes from isolated neonatal rats, through the cyclic guanosine monophosphateYdependent protein kinase, focal adhesion kinase, or extracellular signalY regulated kinase and protein kinase C pathways. 40<44 Furthermore, although there were no significant differences in measured outcomes between E 2 -early and E 2 -late supplementation, E 2 -late supplementation more profoundly limited the adverse effects of ovarian estrogen loss on early mitral annular velocity (e ¶) and cardiac nitric oxide production. Whether the relative reduction in blood pressure in the long term or the E 2 -early supplementation led to compensatory increases in sympathetic activation, offsetting any direct E 2 benefits, remains speculative. As reported by Pechenino et al, 45 delayed administration of estrogen is associated with elevations in inflammatory genes, such as inducible nitric oxide synthase and tumor necrosis factor->, as opposed to early administration, which prevents these increases. Therefore, the timing of estrogen loss may potentially lead to mechanistic differences between early and late initiation of E 2 that reinforce the cardiac phenotype.
Previous studies concluded that one of the mechanisms by which endogenous estrogens maintain cardiac structure and diastolic function in the adult female mRen2.Lewis rat may be through improved availability of BH 4 , an essential cofactor that allows neuronal nitric oxide synthase to produce nitric oxide rather than reactive oxygen species. 20 Results of the present study confirmed previous findings that estrogen deprivation by OVX reduced cardiac nitrite and BH 4 , and enhanced BH 2 . These effects may increase the production of superoxide in the heart, as opposed to nitric oxide, and also increase filling pressures and deposition of cardiac collagen in comparison with intact littermates. Although the exact mechanisms by which estrogen regulates the bioavailability of cardiac BH 4 are not yet clear, the direct effects of estrogen on the expression of GTP cyclohydrolase I, a key enzyme in the synthesis of BH 4 , may be involved. 46 Perivascular fibrosis is an important cause of diastolic dysfunction in hypertensive and aging hearts, 27,47<49 affecting coronary hemodynamics independently of blood pressure. 47 Coronary vascular resistance and flow reserve have been shown to affect diastolic function in both humans and animal models. 27, 49 A number of studies have demonstrated that E 2 inhibits cardiac fibroblast proliferation and collagen synthesis. 50, 51 In the present study, bilateral OVX increased perivascular fibrosis, and this effect was prevented by E 2 treatment. Despite the differences in serum estradiol and blood pressure, the early and late treatment groups exhibited no differences in the inhibition of cardiac fibrosis, consistent with the lack of differences in cardiac function and structure. In contrast, estradiol treatment for 8 weeks prevented cardiac perivascular fibrosis in ovariectomized SHRs at 10 weeks, but not at 25 weeks. 35 Inconsistencies between studies may be related to the differences in age at which time treatment commenced. Structural changes in the walls of coronary arteries may have been more pronounced in the older SHRs used in the study and could not be restored by estrogen treatment.
Although one primary goal of hormone therapy in perimenopausal and early postmenopausal women is the relief of vasomotor and/or urogenital symptoms, several small studies provide clinical evidence that exogenous estrogens might reverse or delay menopause-associated diastolic dysfunction. Fak et al 52 showed that a single oral dose of conjugated equine estrogens (0.625 mg) significantly improved isovolumic relaxation time and nearly normalized the E/A ratio in hypertensive postmenopausal women, whereas the same dose given to normotensive postmenopausal women had no effect. Alecrin et al 53 showed that 12 weeks of oral estradiol (1.0 mg/d) administration significantly improved isovolumic relaxation and early deceleration time, and increased the E/A ratio in hypertensive postmenopausal women when compared with placebo-treated women with similar characteristics. Using both conventional and tissue DopplerYderived indices of diastolic function, Duzenli et al 54 demonstrated that 6 months of hormone therapy (oral conjugated estrogens 0.625 mg/d + medroxyprogesterone acetate 2.5 mg/d) positively affected diastolic function and improved exercise capacity in normotensive women who were within 3 years of menopause. Whether hormone therapy can improve diastolic function in older hypertensive women with more than 10 years of estrogen deficiency is not known.
When extrapolating to the clinical scenario, there are a few practical limitations that should be considered. First, the OVX rodent model leads to abrupt menopause and does not simulate the hormonal cycling of perimenopausal women. In addition, unlike OVX rats, 90% of postmenopausal women still have their ovaries. The postmenopausal ovary remains hormonally active, secreting significant amounts of androgens and estrogens, 55 which could influence cardiovascular tissue and function. Future studies using 4-vinylcyclohexene diepoxide in mRen2.Lewis rats could help delineate differences in diastolic function between transitional and surgical menopause in women. 56, 57 Second, we did not monitor the physical activity of the rats, which could have positive effects on diastolic function. Clinical and experimental studies show that aerobic training limits age-related changes in diastolic function and arterial stiffness 58<60 and might also add to the cardiovascular benefits of hormone therapy. 61 Even so, the rats in this study were pair-housed and not exposed to freewheel running.
CONCLUSIONS
The results of the present study demonstrate that E 2 -early and E 2 -late treatments attenuated estrogen deprivationYinduced diastolic dysfunction and cardiac remodeling to similar extents in female mRen2.Lewis rats, independent of final blood estradiol concentration and blood pressure. Previous studies using animal models found that a protracted delay between estrogen deprivation and replacement led to significant changes in cardiac gene expression, so that the status of cardiac tissue was markedly different when estrogen production ceased and replacement started. 45 It is probable that gene expression and cardiac tissue status were different when the early and late treatments were initiated in the present study, but further studies are necessary to determine the
